Kushen Mahuang Injection Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a purified multi-alkaloid botanical intermediate manufactured from co-processed roots of Sophora flavescens Aiton and aerial stems of Ephedra sinica Stapf or Ephedra equisetina Bunge. The material is not a crude herbal powder and is not a finished injectable; it is a sterile-filterable, low-endotoxin extract standardized for marker alkaloid content and intended for further pharmaceutical unit operations. The product is supplied as lyophilized powder or concentrated liquid suitable for dilution into aqueous solutions, dry blends, wet granulation media, or non-aqueous coating systems. In injectable manufacturing, the API is dissolved in Water for Injection, pre-filtered through 0.45 µm polyethersulfone membranes, and subsequently sterile-filtered through 0.22 µm membranes under ISO 14644-1:2015 Class 5 unidirectional airflow. The formulation route determines whether the API is used as a solubility-adjusted concentrate, a dry dispersion, or a co-processed granule component.

Which pharmacopoeial release criteria apply to a botanical multi-alkaloid API?

Release testing for this material follows a combination of Chinese Veterinary Pharmacopoeia 2020 general chapters, USP <621> for chromatographic assay, USP <85> for bacterial endotoxins, and ICH Q3D for elemental impurity risk assessment. No single harmonized monograph exists for the co-processed Kushen-Mahuang injection-grade intermediate; the specification profile is therefore constructed from the parent herbal monographs and the intended dosage route. A manufacturer-designated model code, such as KSMH-VG-10:1-05-API, may encode native extraction ratio, total alkaloid target, and physical form, but the code structure is not harmonized and must be interpreted against the certificate of analysis.

Typical release criteria include identification of ephedrine, pseudoephedrine, matrine, and oxymatrine by retention time and UV spectrum against certified reference standards. Assay limits are normally set at 90.0–110.0% of label claim for total ephedrine alkaloids and total matrine-type alkaloids, with an ephedrine-to-pseudoephedrine ratio declared by the manufacturer. Because Ephedra biomass alkaloid content can vary by region and harvest period, marker normalization is more meaningful than native extract ratio alone. Loss on drying for lyophilized powder is generally controlled to not more than 5.0% w/w; microbiological limits follow the intended route, with sterile APIs requiring compliance to USP <71> sterility testing when labelled as such.

Storage conditions should maintain container closure integrity below 25°C, with desiccant when the powder form is used at relative humidity above 60%. The lyophilized powder is hygroscopic because residual alkaloid salts and non-alkaloid saccharides can absorb atmospheric moisture, reducing flowability and compressibility. Re-drying does not reliably recover the original compaction characteristics; therefore, direct compression formulations require validated moisture tolerance rather than post-hoc drying correction.

When terminal sterilization is unavailable for the injection route

If the finished injectable cannot be terminally sterilized at 121°C for 15 min, aseptic filtration becomes the default manufacturing route. The primary process risk is membrane fouling from residual high-molecular-weight polysaccharide and denatured plant protein fractions. A two-stage filtration train consisting of 0.45 µm clarification followed by 0.22 µm final sterile filtration is required; single-stage filtration of unclarified API solution frequently exceeds filter capacity and produces batch rejection due to filter blockage.

Alkaloid solubility is pH dependent. At pH above 7.5, ephedrine free base may precipitate as a waxy film on vessel walls and filter surfaces. Injectable formulations are therefore maintained in the range pH 4.5–6.5 unless a specific salt form is selected to improve solubility. Autoclaving above 121°C should not be assumed to be inert: thermal stress can shift the oxymatrine-to-matrine ratio, and the resulting marker profile may fall outside release specifications. Published data for this specific conversion in the finished veterinary dosage form is limited; a forced degradation study under ICH Q1A conditions is required before establishing a terminal sterilization cycle.

For parenteral solutions, particulate matter should be evaluated according to USP <788>. Large-volume parenteral criteria of not more than 25 particles/mL ≥10 µm and not more than 3 particles/mL ≥25 µm apply unless regional veterinary pharmacopoeia thresholds differ. Botanical APIs with non-alkaloid fractions can generate subvisible particles after heat stress, so particle count testing should be performed at release and at the end of the proposed shelf life.

For oral premix and dry powder applications, the API powder is introduced at a low inclusion rate and requires geometric dilution to achieve blend uniformity. A ribbon blender or paddle blender is operated until the coefficient of variation for marker alkaloid content is below 5.0%. Sieve analysis according to ISO 2591-1:2008 should define D10, D50, and D90. A D90 above 150 µm can lead to segregation during transfer, while co-milling to D90 below 120 µm improves distribution but may increase amorphous content and hygroscopic caking. Premix carriers should be selected for low reducing sugar content because ephedrine-type secondary amines can undergo Maillard browning with lactose or dextrose carriers under heat and moisture, causing assay loss and visible discoloration.

Tablet and capsule processing boundaries

Direct compression of this API requires an understanding of its predominantly brittle-fracturing compaction behaviour. Blends containing microcrystalline cellulose and sodium starch glycolate improve compactibility, but the API should not be layered onto pellets by aqueous spray without a binder system that tolerates residual alkaloid pH. In capsule filling, the API is commonly pre-blended with lactose monohydrate and sieved through 0.600 mm mesh; if the alkaloid bitterness is unacceptable, taste masking may require solvent-based ethylcellulose coating or lipid coating rather than simple sugar coating. Compatibility between the coating polymer and alkaloid salts should be confirmed by differential scanning calorimetry, because residual alkaloid fractions can plasticize certain methacrylic acid copolymers and alter release profiles. Adhesion data for this specific API in enteric-coated veterinary capsules is limited, and pan-coating parameters must be established experimentally rather than transferred directly from synthetic active formulations.

Comparing botanical multi-alkaloid APIs with synthetic single-entity actives

The difference between this product and single-entity ephedrine hydrochloride is not limited to biological source. Synthetic ephedrine hydrochloride has a molecular mass of 201.69 g/mol and behaves as a crystalline single component with predictable dissolution and compactibility. The botanical API is a multi-component extract containing quinolizidine alkaloids from Kushen, phenylpropanolamine-type alkaloids from Mahuang, and residual flavonoids, saponins, and polysaccharides. These co-extractives contribute color, hygroscopicity, injection-site reactogenicity, and chromatographic interferences that require higher specification resolution than synthetic actives.

Regulatory classification also differs by jurisdiction. The botanical API may be subject to residue depletion and withdrawal period requirements in food-producing species, particularly where ephedrine alkaloids are controlled or prohibited. The synthetic single-entity product typically has a well-characterized impurity profile, while the botanical intermediate requires batch-to-batch marker ratio traceability against a declared pilot-scale reference standard. Facilities switching from synthetic ephedrine hydrochloride to this multi-alkaloid API should not assume that cleaning validation limits, filter sizing, or dissolution specifications remain unchanged.

Microbial and endotoxin control for solution and injection formats

Solutions manufactured from this API should be evaluated for bioburden and endotoxin before final batching. If the API is labelled injection grade, the bacterial endotoxin acceptance criterion is usually set below 0.5 EU/mg, although the final product limit must be derived from dose and species. For large-volume parenteral solutions, particulate matter must comply with USP <788> limits of 25 particles/mL ≥10 µm and 3 particles/mL ≥25 µm. End-product depyrogenation by dilution alone is insufficient; endotoxin removal requires upstream process control, activated carbon adsorption, or ultrafiltration, and each step may reduce alkaloid yield. If gamma irradiation is used for non-sterile oral powder, the absorbed dose must not be assumed to be inert: forced degradation data are required to demonstrate that alkaloid marker ratios and physical dissolution profiles remain within registered limits.

Cross-contamination control is a significant operational boundary when shared fluid-bed dryers, granulators, or capsule fillers are used for this botanical API and conventional synthetic actives. Ephedrine alkaloid residues are pharmacologically potent and require cleaning validation based on permitted daily exposure rather than visual cleanliness alone. Analytical verification by HPLC-MS/MS with a limit of quantification at or below 0.1 µg/cm² is recommended for shared facilities. Strong oxidizing agents such as hypochlorite may degrade residual alkaloid films and produce discolored surfaces; hot water with alkaline detergent followed by rinse verification is the more common cleaning sequence. Dedicated equipment for this botanical API reduces cross-contamination risk in food-producing animal operations, but it is not explicitly required if validated cleaning and line clearance procedures are documented.